Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK5926371 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT07607925Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Primary completion
- Jan 2030
- Countries
- 8
01
Overview
A Phase 2 trial of GSK5926371 in non-Hodgkin lymphoma (NHL), sponsored by GSK. Started Jun 2026; status: recruiting.
02
Drugs
GSK5926371
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07607925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607925.